User:Mr. Ibrahem/Lenvatinib

Lenvatinib, sold under the brand name Lenvima among others, is medication used to treat certain types of thyroid cancer, renal cell cancer, and hepatocellular carcinoma. For thyroid cancer, it is used when radioactive iodine is not effective. It is taken by mouth.

Common side effects include high blood pressure, diarrhea, weight loss, nausea, inflammation of the mouth, headache, and rash. Other side effects may include kidney problems, heart failure, blood clots, bleeding in the brain, and liver problems. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor against VEGFR1, VEGFR2 and VEGFR3.

Lenvatinib was approved for medical use in the United States and Europe in 2015. In the United Kingdom it costs the NHS about £1,400 at a dose of 10 mg per day for a month as of 2021. In the United States this amount is about 21,300 USD.